The Japan Ministry of Health, Labour and Welfare has approved Genmab’s Tivdak (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after chemotherapy treatment.   Tivdak is the first antibody-drug conjugate (ADC) to be approved for people living with cervical cancer in Japan.  In recent years, cervical cancer incidence […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!